Literature DB >> 27287688

Benign form of myasthenia gravis after nivolumab treatment.

Giorgia Sciacca1, Alessandra Nicoletti1, Luigi Rampello1, Laura Noto2, Hector J Soto Parra2, Mario Zappia1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27287688     DOI: 10.1002/mus.25212

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


× No keyword cloud information.
  6 in total

1.  Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.

Authors:  Justin C Kao; Bing Liao; Svetomir N Markovic; Christopher J Klein; Elie Naddaf; Nathan P Staff; Teerin Liewluck; Julie E Hammack; Paola Sandroni; Heidi Finnes; Michelle L Mauermann
Journal:  JAMA Neurol       Date:  2017-10-01       Impact factor: 18.302

Review 2.  Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.

Authors:  Justin C Kao; Adipong Brickshawana; Teerin Liewluck
Journal:  Curr Neurol Neurosci Rep       Date:  2018-08-04       Impact factor: 5.081

3.  Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report.

Authors:  Yu-Hsiu Chen; Feng-Cheng Liu; Chang-Hung Hsu; Chih-Feng Chian
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

Review 4.  Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Caberry W Yu; Matthew Yau; Natalie Mezey; Ishraq Joarder; Jonathan A Micieli
Journal:  Eye Brain       Date:  2020-11-03

5.  Neurotoxicity: A Rare Side Effect of Programmed Cell Death 1 (PD-1) Inhibitors.

Authors:  Syed Ehsanullah; Syed Hasan; Faran S Polani; Syeda Zarmeena Rashid; Syed Ijlal Ahmed
Journal:  Cureus       Date:  2022-02-24

Review 6.  Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.

Authors:  Jia-Hung Chen; Kang-Yun Lee; Chaur-Jong Hu; Chen-Chih Chung
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.